Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients by Jabłonowska, Elżbieta et al.
RESEARCH ARTICLE
Real-life study of dual therapy based on
dolutegravir and ritonavir-boosted darunavir
in HIV-1-infected treatment-experienced
patients
Elżbieta JabłonowskaID1*, Ewa Siwak2, Monika Bociąga-Jasik3, Jacek Gąsiorowski4,
Anna Kalinowska3, Ewa Firląg Burkacka2, Kamila Wójcik-Cichy1, Anna Piątek3,
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Abstract
Background
Dual therapy based on dolutegravir and ritonavir-boosted darunavir (DTG/DRV/r) is a com-
bination of well-known drugs with a high genetic barrier to HIV resistance.
Method
A retrospective analysis of all HIV-1 infected treatment-experienced patients who switched
to DTG/DRV/r from May 2014 till March 2017 in 4 Polish centres–results of a 48-week
treatment.
Results
The study group consisted of 59 men and 17 women. Median baseline parameters were:
age– 42.7 years, CD4 cells count– 560.5 cells/μl, CD4 cells nadir– 150 cells/μl, number of
prior antiretroviral regimens– 3. The introduction of dual therapy was primarily due to viro-
logic failure (30 patients), adverse events on previous regimens (17 patients) and therapy
simplification (27 patients). At week 48 the treatment was continued in 70/76 of patients and
the median CD4 cells count increased from 560.5 to 641.0 cells/μl. The therapy was discon-
tinued in six patients (1 –virologic failure, 1 –decrease of estimated glomerular filtration rate
(eGFR), 1 –myalgia, 3 –lost to follow-up). At week 48 six patients had detectable viremia,
but only in one patient viremia was higher than 200 copies/ml. At week 48 the level of serum
total cholesterol of the investigated subjects was statistically significantly higher than at the
moment of dual therapy introduction (185.8 mg/dl vs. 174.8 mg/dl- p<0.05). However, in
patients previously not treated with TDF, there were no changes in lipid parameters during
PLOS ONE | https://doi.org/10.1371/journal.pone.0210476 January 17, 2019 1 / 10
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Jabłonowska E, Siwak E, Bociąga-Jasik
M, Gąsiorowski J, Kalinowska A, Firląg Burkacka E,
et al. (2019) Real-life study of dual therapy based
on dolutegravir and ritonavir-boosted darunavir in
HIV-1-infected treatment-experienced patients.
PLoS ONE 14(1): e0210476. https://doi.org/
10.1371/journal.pone.0210476
Editor: Cristian Apetrei, University of Pittsburgh
Centre for Vaccine Research, UNITED STATES
Received: September 17, 2018
Accepted: December 25, 2018
Published: January 17, 2019
Copyright: © 2019 Jabłonowska et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
therapy. Proteinuria was observed in 13.2% of patients before the switch to dual therapy
and in 7.1% of patients at week 48.
Conclusions
The investigated dual therapy was effective and safe. The observed increase in lipid param-
eters only concerned the patients who had used a TDF-based regimen prior to analysed
dual treatment.
Introduction
Due to the introduction of combined antiretroviral therapy (cART), persons infected with the
Human Immunodeficiency Virus (HIV) are currently able to live almost as long as non-
infected subjects. The therapy increases the number of CD4+T lymphocytes (CD4 cells),
which is the key factor determining life expectancy of HIV-positive people [1]. Considering
that the introduction of cART is recommended for all HIV-infected patients [2, 3], also young
people with a high CD4 cells count are subject to a lifelong treatment. In the era of modern
cART, which includes very potent drugs with improving tolerability profiles, the choice of an
optimal combination becomes more and more dependent on adverse events, which may occur
in the long term.
For more than twenty years, triple drug combinations have remained a standard of care for
HIV infection. Current guidelines recommend a combination of two backbone drugs–namely
abacavire (ABC) and lamivudine (3TC) or tenofovire (TDF or TAF) and emtricitabine (dTC)–
with a third drug from another antiretroviral (ARV) group, for all patients who start treatment
[2, 3].
At the same time, long experience with triple combinations shows not only their benefits in
terms of antiviral efficacy, but also the associated side effects [2, 4–10]. Indeed, both backbone
regimens are known of long-term cumulative adverse events. Tenofovir can cause proximal
renal tubulopathy, reduce the glomerular filtration rate (GFR) and decrease the bone mineral
density [4, 5, 11, 12], while abacavir can increase the risk of cardiovascular diseases [13–15].
Moreover, since both drugs belong to a group of nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs), and are thus characterized by a low genetic barrier to resistance [16], the
recommended regimens may not be suitable for patients in whom such resistance occurs. Both
factors highlight the importance of sharing the experience with non-standard regimens across
the medical community.
Aim
The study aimed to evaluate the efficacy and tolerability of the dual therapy containing dolute-
gravir and ritonavir-boosted darunavir (DTG/DRV/r).
Material and methods
Retrospective analyses of medical records were performed in four Polish HIV centres with a
view to identifying the number of HIV-1 infected treatment-experienced patients who
switched to DTG/DRV/r from May 2014 till March 2017. All patients who fulfilled these con-
ditions were included into the study. Medical data from the moment of dual therapy introduc-
tion and at the 48 week of treatment were collected and assessed.
DTG/DRV/r -observational study
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To evaluate the use of the DTG/DRV/r regimen in a real-world setting, the exclusion crite-
ria were not established. Notwithstanding the above, no mutations associated with DRV or
DTG resistance had been confirmed in the investigated patients before the dual therapy was
introduced. However, in most studied patients, the integrase genotypic testing was not per-
formed. The virologic failure of this therapy before 48 week of treatment was defined as stop-
ping dual therapy because of lack of virological response—doctor decision or viral load above
50 copies/ml at 48 week. Effectiveness of dual therapy was measured as a proportion of patients
continuing this treatment throughout the investigated period of 48 weeks.
The measurements of lipid parameters, CD4 cells count, estimated glomerular filtration
rate (eGFR) and proteinuria performed at two time points–before the introduction of DTG/
DRV/r therapy (maximum 3 months) and after 48 weeks of dual treatment (±8 weeks)–formed
the basis of the relevant comparisons. The assessment of GFR was performed using the Modifi-
cation of Diet in Renal Disease Study formula [17]. The CD4 cells count was established by
means of flow cytometry. Creatinine concentration and HIV viremia were determined using
the kinetic compensated Jaffe method and RT-PCR method (Cobas AmpliPrep/Cobas Taq-
Man HIV-1 Test, Roche Diagnostics), respectively. To assess proteinuria dipstick analyses
were performed. The levels of serum total cholesterol (TC) and triglycerides (TG) were mea-
sured using traditional enzymatic methods. The Low-density lipoprotein cholesterol (LDL-C)
fraction was estimated by means of Friedewald formula, provided that the level of triglycerides
did not exceed 400 mg/dl. If this was not the case, the measurements of LDL-C were per-
formed by direct methods.
The study was approved by the ethics committee (Medical University of Lodz). All patients
signed the informed consent form. All data were analysed anonymously.
Statistical methods
The differences in CD4 cells count, TC, LDL-C and TG before the introduction of the dual
therapy and at 48 weeks of treatment were assessed by means of paired sample T test or Wil-
coxon signed-rank test. For categorical parameters, such as the presence of proteinuria and
eGFR<60ml/min/1.72m2, the McNemar test was used.
Results
Study group
The study group consisted of 76 HIV-1-infected patients (59 males and 17 females) with a
median age of 42.7 years. Homosexual and bisexual contacts were identified as the main route
of HIV transmission. All subjects were treatment-experienced with the median number of
prior antiretroviral regimens equal to 3. At the moment of dual therapy introduction, the
median CD4 cell count was 560.5 cells/μl. The parameters of the study group are presented in
Table 1. The regimens administered directly before the switch to DLT/DRV/r treatment are
presented in Table 2.
The reasons for the introduction and for the discontinuation of DLT/DRV/
r treatment
The DTG/DRV/r therapy was most commonly introduced as a response to a virologic failure
on previous regimens. In 27 patients the reason for the switch to DTG/DRV/r was simplifica-
tion of the treatment. A combination, which had been replaced most frequently for this reason,
was a regimen based on RAL/DRV/r with a twice-daily RAL dosing (14 patients).
All reasons for the introduction of DTG/DRV/r are presented in Table 3.
DTG/DRV/r -observational study
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The dual therapy was stopped in six patients, one of whom experienced virologic failure (at
week 48). Three patients were lost to follow-up before 48 weeks of treatment–in these patients
viremia was not assessed during the dual therapy. In two patients adverse events were the rea-
son for stopping dual therapy (Fig 1).
Virologic response
At 48 weeks (+/- 4 weeks) viral load was above 50 copies/ml in six patients, of whom only in
one subject the threshold of 200 copies/ml was exceeded. The treatment was discontinued in
this patient, even though no mutations in the genotyping test were found. Five patients with
viremia lower than 200 copies/ml remained on DTG/DRV/r therapy.
The assessment of immunologic failure, renal safety and lipid profile after
48 weeks of dual therapy (+/- 6 weeks)
We found a statistically significant increase in the CD4 cells count (median 80.5 cells/μl) and
in TC level. By contrast, no statistically significant changes were found in LDL-C and TG levels
(Table 4). The number of subjects with lipids abnormality at baseline and at week 48 is pre-
sented in Fig 2. Proteinuria was observed in 13.2% of patients before the switch to dual therapy
and in 7.1% at week 48 (p>0.05); eGFR<60 mL/min/1.72m2 was noted in 10.5% before the
switch to dual therapy and in 12.7% at week 48 (p>0.05).
Table 1. Characteristics of study group.
n %
Men 59/76 77.6
Routes of HIV transmission Intravenous drug use 19/76 25.0
Heterosexual 11/76 14.5
Homosexual/bisexual 44/76 57.9
Other/unknown 2/76 2.6
MEDIAN LQ-UQ
Age at the moment of HIV infection diagnosis (years) 33.6 27.5–40.7
Age at the moment of the introduction of dual therapy 42.7 37.8–52.0
Lymphocyte CD4+ at the moment of the introduction of dual therapy (cells/μl) 560.5 362.5–756.3
Lymphocyte CD4+ nadir (cells/μl) 150.0 80.5–328.0
Number of prior antiretroviral regimes 3 2–5
https://doi.org/10.1371/journal.pone.0210476.t001
Table 2. ARV regimens directly before the switch to DLT/DRV/r.
Type of therapy N (%)
Standard three-drug combination with two NRTIs and one boosted PI 39
Standard three-drug combination with two NRTIs and one NNRTI 4
Standard three-drug combination with two NRTIs and one InI 4
Two- drug combination 19
Non-standard three-drug combination 6
Four-drug combination 4
NRTI—nucleoside/nucleotide reverse transcriptase inhibitors
NNRTI-non-nucleoside reverse transcriptase inhibitorsPI- protease inhibitors
InI- integrase inhibitors
https://doi.org/10.1371/journal.pone.0210476.t002
DTG/DRV/r -observational study
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Table 3. Reasons for the introduction of DTV/DRV/r.
Reason n
Adverse events
n = 17
Osteopenia/osteoporosis 3
Kidney disorder 5
Hematologic disorders 1
Hypersensitivity reaction to NRTIs 1
Acidosis 1
Polineuropathy 2
Pancreatitis 1
Other intolerance 3
Treatment failure
n = 30
Virologic failure 30
Other reasons
n = 29
Simplification of therapy 27
Other 2
Total 76
https://doi.org/10.1371/journal.pone.0210476.t003
Fig 1. Algorithm of the study population. DTG/DRV/r = dolutegravir and ritonavir-boosted darunavir.
https://doi.org/10.1371/journal.pone.0210476.g001
DTG/DRV/r -observational study
PLOS ONE | https://doi.org/10.1371/journal.pone.0210476 January 17, 2019 5 / 10
Analysis of the factors which could have affected the increase of cholesterol levels Medical
records of the study group in the analysed period did not find any of the patients who had
taken cholesterol-lowering drugs to have interrupted such treatment or begun alcohol abuse.
At week 48, statin intake was commenced in 1 patient, 5 patients were diagnosed with alcohol
abuse, yet this had already been the case before the switch of the treatment, and 2 patients were
reported to quit smoking.
Since a positive impact of TDF on lipid parameters was found in other studies, in order to
assess whether the observed increase in cholesterol levels was related to the discontinuation of
this drug, a targeted analysis of lipid concentrations in the study group was performed. For
purpose of this assessment a distinction was made between patients who had taken TDF as
Table 4. Comparison of results before the introduction of DTG/DRV/r therapy and at 48 weeks of treatment.
Before the introduction of DLT/DRV/r 48 weeks of treatment P
MEDIAN (LQ- UQ) Mean ±SD MEDIAN (LQ- UQ) Mean ±SD
Lymphocyte CD4+ (cells/μl) 560.5
(362.5–756.3)
560.7±276.6 641.0
(433.5–801.5)
639.6±280.6 <0.0001
Lymphocyte
CD4+/CD8+
0.7
(0.4–0.9)
0.7±0.3 0.7
(0.5–0.9
0.7±0.3 <0.0001
Total cholesterol (mg/dL) 174.8
(150.2–192.3)
173,8±34.9 185.8
(161.3–200.8)
186.5±36.1 <0.05
Cholesterol LDL (mg/dL) 98.7
(77.6–119.9)
97.37±29.4 103.7
(83.7–119.1)
101.6±27.8 >0.05
Triglyceride (mg/dL) 132.0
(90.0–185.1)
159.3±97.6 138.1
(100.0–202.7)
170.6±108.8 >0.05
https://doi.org/10.1371/journal.pone.0210476.t004
Fig 2. Number of subjects with lipids abnormality at baseline and week 48 TC -total cholesterol, LDL-C—Low-density lipoprotein
cholesterol, TG -triglyceridep>0.05 for all comparison.
https://doi.org/10.1371/journal.pone.0210476.g002
DTG/DRV/r -observational study
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part of their previous regimens (45 subjects) and patients who had not taken this drug prior to
the introduction of the analysed dual treatment (31 subjects). The increase in total cholesterol
level and LDL cholesterol at 48 weeks of treatment was found in patients with previous TDF
intake. No changes in lipid parameters were observed in the second subgroup (Table 5).
Discussion
Despite the fact that NRTIs can induce the mitochondrial toxicity three-drug combinations
based on NRTIs have remained a preferred regimen for the treatment of HIV-infected patients
since at least two decades [2, 3]. However nowadays a growing number of studies focuses on
dual regimens, which do not include NRTIs [18–24]. In our previous study the efficacy and
safety of a dual regimen based on raltegravir (RAL) and DRV/r was analysed. The regimen was
found to be effective in most patients, yet the inconvenience of having to administer drugs
twice per day resulted in a switch of therapy to DTG/DRV/r in some of the studied subjects.
When we realized that there were more patients taking this combination of drugs in different
Polish centres, we decided to retrospectively analyse the results of such treatment.
When a new combination of drugs is introduced there are many concerns about its safety
and efficacy. Theoretically a combination composed of DTG/DRV/r should be more effective
than other dual therapies because of a high genetic barrier to resistance of both drugs [9, 25,
26]. However, not only the strength of individual components, but also other factors can have
an influence on the safety and efficacy of a regimen. Fortunately pharmacokinetic data show
adequate steady-state drug concentrations of these drugs combined together [27]. In reference
to safety and tolerability of the investigated combination the same risks as those connected
with its individual components can be expected, in addition to which other unexpected issues
may occur. DTG is known of an excellent tolerability profile but lately raised some concerns
about neurological side effects [8, 9, 28]. DRV/r, like other protease inhibitors, is known of an
unfavourable metabolic profile, but is still the most favourable one within this group [9].
Our results indicate that a combination of DTG and DRV/r is well tolerated and effective,
as demonstrated by the fact that 92.1% of patients remained on therapy throughout the investi-
gated period of 48 weeks. It is worth stressing that in one patient, in whom the therapy was dis-
continued because of virologic failure, no mutations associated with DRV or DTG resistance
were found. A high virologic response and a good tolerability was also found in an Italian
Table 5. Lipids changes during therapy in subgroups according to the prior TDF intake.
Patients treated with TDF
Before the introduction of DTG/DRV/r 48 weeks of treatment P
MEDIAN (LQ- UQ) Mean ±SD MEDIAN (LQ- UQ) Mean ±SD
Total cholesterol (mg/dL) 179.0
(142.8–190.0)
171.7±35.3 185.7
(158.7–199.2)
181.8±34.3 <0.01
Cholesterol LDL (mg/dL) 101.5
(67.0–119.6)
93.5±30.9 103.7
(88.0–115.2)
101,8±24,8 <0.05
Triglyceride (mg/dL) 113.1
(88.0–172.8)
143.6±93.1 115.6
(90.0–177.0)
156.5±113.7 >0.05
Patients treated without TDF
Total cholesterol (mg/dL) 173,4
(162.1–197.4)
176.4±35.0 188.08
(164.9–202.0)
192.4±38.1 >0.05
Cholesterol LDL (mg/dL) 99.85
(85.9–122.3)
102.1±27.1 106.81
(77.8–126.9)
101.5±31.5 >0.05
Triglyceride (mg/dL) 136.40
(113.0–227.4)
178.4±101.1 155.0
(109.8–233.8)
187.8±101.8 >0.05
https://doi.org/10.1371/journal.pone.0210476.t005
DTG/DRV/r -observational study
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study where 90.8% of investigated patients who switched to DTG/DRV/r had viral load below
50 copies/ml at week 48 of the treatment [19].
Further attention is drawn to the heterogeneity of our study group along with the previous
ARV experience of all investigated subjects. Indeed, the study was not limited to patients in
whom the dual regimen was introduced due to a virologic failure or adverse events on previous
regimens. It also encompassed individuals who had previously been subject either to a salvage
therapy, or to a dual therapy based on RAL/DRV/r as mentioned above. While the aforemen-
tioned situations do not exhaust all possible reasons for the introduction of DTG/DRV/r, they
certainly reveal the heterogeneity of the studied population as reflected in our study group. In
our view this heterogeneity is not a limitation, but rather an advantage of this non-interven-
tional study as it shows the efficacy and safety of the analysed dual combination in a real life
setting.
In our study, after the switch to the dual regimen a lower incidence of proteinuria was
found, while an increase of eGFR during therapy was not established. It is known that DTG
may cause an increase in creatinine concentrations as a result of inhibiting organic cation
transporter 2 and a consequent reduction in tubular secretion of creatinine. This increase is,
however, not associated with a decrease of GFR [9].
We did not find central nervous system adverse events to be the reason for therapy discon-
tinuation, which can imply that such events either did not occur, or occurred with low inten-
sity. The only negative impact of the new regimen was a statistically significant increase in the
total cholesterol level. Nevertheless, this did not lead to a change of the administered regimen
and was observed only in patients who had previously taken TDF. The increase in lipid param-
eters was also observed in other studies in which the switch from TDF to a different drug was
investigated. The mechanism in which TDF reduces cholesterol concentration is not clear
[29].
Our observational study has limitations, including the lack of a control group; however, our
results suggest that DTG with DRV/r can present a viable option for selected groups of ARV-
experienced patients.
In summary, the investigated dual therapy was effective and safe. In patients previously
treated with TDF switching to DTG/DRV/r can cause an increase in total and LDL cholesterol
levels.
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